Summary
Neurocrine Biosciences Inc (Neurocrine) is a bio-pharmaceutical company that discovers, develops and commercializes innovative pharmaceutical products for the treatment of neurological and endocrine related diseases and disorders. The company’s products help to treat disease conditions such as endometriosis, anxiety, depression, pain, and other neurological and endocrine related diseases and disorders. The lead candidates of the company include elagolix (Phase III), a gonadotropin-releasing hormone (GnRH) antagonist, being developed in partnership with AbbVie Inc., for the treatment of endometriosis; and vesicular monoamine transporter 2 (VMAT2) inhibitor NBI-98854 (Phase III), being developed for the treatment of movement disorders. Other products in the pipeline include corticotropin-releasing factor (CRF) receptor antagonist, being developed for the treatment of stress related disorders; and elagolix in Phase II, being developed in partnership with AbbVie for the treatment of uterine fibroids. Neurocrine is headquartered in San Diego, California, the US.
Neurocrine Biosciences Inc (NBIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Neurocrine Biosciences Enters into Licensing Agreement with Bial 10
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 11
Equity Offering 12
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 12
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 13
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 15
Neurocrine Biosciences Inc - Key Competitors 17
Key Employees 18
Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20List of Tables
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurocrine Biosciences Enters into Licensing Agreement with Bial 10
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 11
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 12
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 13
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 15
Neurocrine Biosciences Inc, Key Competitors 17
Neurocrine Biosciences Inc, Key Employees 18List of Figures
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
